Article
Oncology
Jina Kim, Jason Chia-Hsien Cheng, Taek-Keun Nam, Jin Hee Kim, Byoung Kuk Jang, Wen-Yen Huang, Hiroshi Aikata, Myungsoo Kim, Jung Hyun Kwon, Jinbo Yue, Victor Ho Fun Lee, Zhaochong Zeng, Jinsil Seong
Summary: This study compared the efficacy of liver-directed combined radiotherapy (LD combined RT) with sorafenib in hepatocellular carcinoma patients presenting portal vein tumor thrombosis. The LD combined RT group showed significantly improved overall survival and a higher conversion rate to curative surgery. Despite the multimodality of the treatment, LD combined RT had comparable toxicity rates to sorafenib.
Article
Multidisciplinary Sciences
Chonlakiet Khorprasert, Kanokphorn Thonglert, Petch Alisanant, Napapat Amornwichet
Summary: For individuals with HCC and PVTT in Thailand, limited treatment options are available due to disease extent, poor liver function, and lack of coverage for immuno/targeted therapy. Radiotherapy has become increasingly important in these patients and is considered a safe and effective therapeutic option, with overall survival being closely related to factors such as patient age, tumor size, radiation dose, and tumor/PVTT response. Further research is necessary to validate these findings through prospective randomized trials.
Article
Oncology
Xiaoquan Ji, Zhe Xu, Jing Sun, Wengang Li, Xuezhang Duan, Quan Wang
Summary: This study compared the efficacy and safety of lenvatinib combined with SBRT versus lenvatinib alone for the treatment of HCC patients with PVTT. The combination treatment group exhibited significantly prolonged overall survival, progression-free survival, intrahepatic progression-free survival, and higher objective remission rate. The adverse events in the combined therapy group were manageable and not significantly different from the monotherapy group.
RADIATION ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Shinya Yokoyama, Yoji Ishizu, Takashi Honda, Norihiro Imai, Takanori Ito, Kenta Yamamoto, Tomoyuki Tsuzuki, Masatoshi Ishigami
Summary: Portal vein thrombosis (PVT) in patients with liver cirrhosis may improve spontaneously when large collateral vessels are absent. In these cases, observation without anticoagulation therapy can be considered in expectation of spontaneous reduction of PVT.
HEPATOLOGY RESEARCH
(2022)
Article
Oncology
Boyuan Liu, Zewei Zhou, Yu Jin, Jinying Lu, Dongju Feng, Rui Peng, Hua Sun, Xiaoxin Mu, Changxian Li, Yun Chen
Summary: This study investigates the intrahepatic microbiota in patients with hepatocellular carcinoma (HCC) and reveals the association between the abundance of Stenotrophomonas maltophilia (S. maltophilia) and HCC progression. S. maltophilia activates the TLR-4-mediated NF-kappa B signaling pathway, inducing senescence-associated secretory phenotype (SASP) in hepatic stellate cells (HSCs), leading to HCC development.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Changlu Zhang, Yanan Gao, Chengzhi Du, Geoffrey J. Markowitz, Jing Fu, Zhenxing Zhang, Chunliang Liu, Wenhao Qin, Hongyang Wang, Fan Wang, Pengyuan Yang
Summary: The study identifies a HBV-induced IL8/CXCR1/TGF beta signaling cascade that suppresses antitumor immunity and enhances metastasis in HCC. This provides new potential targets for therapeutic intervention.
Article
Biology
Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, Chai Hong Rim
Summary: This study investigated the oncologic benefits of local treatment including radiotherapy for hepatocellular carcinoma invading the portal vein. The results showed significant survival benefits in patients receiving local treatment compared to best supportive care, especially in those with Child-Pugh classes A and B.
Article
Gastroenterology & Hepatology
Aline Maehringer-Kunz, Franziska I. Meyer, Felix Hahn, Lukas Mueller, Christoph Dueber, Daniel Pinto Dos Santos, Peter R. Galle, Arndt Weinmann, Roman Kloeckner, Sebastian Schotten
Summary: In Western HCC patients, the prevalence of HVTT may be underestimated, and HVTT may commonly occur with PVTT. Although isolated HVTT is less frequent, its impact on survival is similar to that of PVTT once developed.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Review
Oncology
Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che
Summary: This study compared the efficacy of hepatic artery infusion chemotherapy (HAIC) versus sorafenib in patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT). The results showed that HAIC group had significantly higher rates of complete response, partial response, objective response rate, and disease control rate compared to the sorafenib group. Moreover, the overall survival and progression-free survival rates were significantly higher in the HAIC group.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Fang Fang, Bin Qiu, Peng Zhen, Junjie Wang
Summary: This study retrospectively evaluated the efficacy and safety of hypofractionated radiotherapy for portal vein tumor thrombosis (PVTT) in cirrhotic patients with hepatocellular carcinoma. Results showed a high rate of tumor response with complete response in 25% of cases and no severe complications observed.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Abdul Rehman Khan, Xuyong Wei, Xiao Xu
Summary: Portal vein involvement is a feared complication of HCC, with treatment options including a combination of drugs and other modalities depending on the individual patient. While there are various therapeutic options available, the quest for the ideal combination therapy and sequence remains unanswered.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Review
Gastroenterology & Hepatology
Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao
Summary: HCC with PVTT remains a challenging issue with limited therapeutic options. Combination of transarterial chemoembolization and sorafenib is effective, while surgery is not recommended for Vp4 PVTT. Radiotherapy and other new methods show potential to improve survival rates.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
(2022)
Review
Oncology
Hao Sun, Bing Ma, Ning Sun, Han Bai, Xuejian Li, Chengshuo Zhang
Summary: This study compared the oncological prognosis of different perioperative locoregional adjuvant treatments for HCC with PVTT. The results showed that adjuvant therapy with radiotherapy had the lowest hazard ratio for both overall survival (OS) and recurrence-free survival (RFS). It was concluded that perioperative locoregional adjuvant therapy, especially radiotherapy, provides survival benefits and reduces the risk of recurrence for HCC patients with PVTT.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yizhen Fu, Wei Peng, Weixiang Zhang, Zhenyun Yang, Zili Hu, Yanxun Pang, Dandan Hu, Jinbin Chen, Juncheng Wang, Zhongguo Zhou, Li Xu, Minshan Chen, Yaojun Zhang
Summary: In the treatment of advanced hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) have been proven effective. However, the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Surgery
Hiroji Shinkawa, Shogo Tanaka, Shigekazu Takemura, Ryosuke Amano, Kenjiro Kimura, Masahiko Kinoshita, Kanae Takahashi, Shuichiro Matsuzaki, Shoji Kubo
Summary: The study developed two reliable nomograms to predict extrahepatic recurrence and early intrahepatic recurrence of hepatocellular carcinoma after hepatic resection. These nomograms showed good predictive performance and could guide the selection of treatment strategies for hepatocellular carcinoma patients by surgeons.